$WVE -40%. The stock price losing a lot more weight than its do-nothing "body composition" drug. Remember... https://t.co/XATxYYS3zB
$WVE WVE-007 six-month data just released.... 1% placebo-adjusted weight loss! 🤣 https://t.co/DR0Au9V39m
Doing some reading ahead of the next wave of $WVE INHBE "body composition" 🙄 data, smirking at the Jefferies analyst set up, which basically frames 6-month data as a win-win-win for the stock price. His "bear case" "Bear case would still set WVE-007 up to be a viable option for obesity treatment given at low dose and early timepoint, but it may not be a strong monoTx, and instead potentially a maintenance or add-on/combo therapy with SoC."
This is the Grade 5 SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency
$ARWR another INHBE targeted drug with no weight loss. Missing 24-week data Miniscule Ns (and an omitted patient) in combo tirzepatide arm But hey, who needs data when you can just sell a cool story? Like $WVE
In this week's Biotech Scorecard newsletter: $WVE Wave’s ‘gym bro’ obesity drug is story over substance https://t.co/XATxYYS3zB
$2 billion of stock being offered tonight, collectively, from $GPCR $DYN $VERA $FULC $WVE $KYMR and it's only 4:06 pm.
$WVE We've entered the "patients are heavier is good!" phase of the obesity hype cycle.
Happy Monday morning! Should be a busy one, with weekend ASH stock trading + $KYMR $DYN $GPCR $WVE data readouts. And, of course, everyone will be buying more $ABVX
